Urine Test News and Research

RSS

Detecting dangerous blood clots in the form of simple urine test

Detecting dangerous blood clots, which can cause life-threatening conditions such as strokes and heart attacks, leading causes of death for men and women in the U.S., has been a coveted and elusive goal.

17 Oct 2013

Simple urine test uses nanotechnology to detect dangerous blood clotting

Life-threatening blood clots can form in anyone who sits on a plane for a long time, is confined to bed while recovering from surgery, or takes certain medications.

17 Oct 2013

Key marker in blood and urine identifies genetic mutations in gene responsible for RP

Research led by physician-scientists at Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has produced a breakthrough discovery in diagnosing retinitis pigmentosa, a blinding disease that affects about 1 in 4,000 people in the United States.

16 Oct 2013

Researchers make breakthrough discovery in diagnosing retinitis pigmentosa

15 Oct 2013

Retinitis pigmentosa test identifies mutation found in Ashkenazi Jewish population

You might not think to look to a urine test to diagnose an eye disease. But a new Duke University study says it can link what is in a patient's urine to gene mutations that cause retinitis pigmentosa, or RP, an inherited, degenerative disease that results in severe vision impairment and often blindness. The findings appear online in the Journal of Lipid Research.

9 Oct 2013

New ultra-specific test now available for prostate cancer

A new urine test for prostate cancer that measures minute fragments of RNA is now commercially available to men nationwide through the University of Michigan MLabs.

27 Sep 2013

University of Michigan offers new test to improve PSA screening for prostate cancer

More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.

26 Sep 2013

Research Institute at Nationwide Children's Hospital to receive transition-to-scale grants

he Saving Lives at Birth: A Grand Challenge for Development recently shortlisted 53 finalists from around the world from more than 400 entries. Only 22 teams were awarded grants for their bold, new ideas to save the lives of mothers and newborns in developing countries.

27 Aug 2013

Noninvasive urine test can accurately monitor risk of kidney rejection

Levels of a protein in the urine of kidney transplant recipients can distinguish those at low risk of developing kidney injury from those at high risk, a study suggests. The results also suggest that low levels of this protein, called CXCL9, can rule out rejection as a cause of kidney injury.

23 Aug 2013

3-gene signature test will improve care of kidney transplant patients

A breakthrough non-invasive test can detect whether transplanted kidneys are in the process of being rejected, as well as identify patients at risk for rejection weeks to months before they show symptoms, according to a study published in The New England Journal of Medicine (NEJM).

4 Jul 2013

Research shows PODXL protein contributes to aggressive forms of bladder cancer

Aggressive forms of bladder cancer involve the protein PODXL - a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

24 May 2013

Simple urine test picks up mesalamine non-adherence

A readily available urine test could identify ulcerative colitis patients who are non-adherent to their mesalamine therapy, research shows.

25 Jan 2013

New diagnostic innovations could refine the way doctors detect prostate cancer

Despite the volume of prostate cancer tests and treatments, experts and their patients are continually challenged to predict the disease's course and apply the most appropriate treatment. Now, two new diagnostic innovations – the PCA3 urine test and a more targeted prostate biopsy technique - could refine the way doctors diagnose prostate cancer and, subsequently, the way patients elect to treat it.

15 Dec 2012

Study questions value of coated, low-dose aspirin therapy

Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets - blood cells that clump together in the first stages of forming harmful clots - up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.

6 Dec 2012

September issue of JNCCN publishes two prostate cancer articles

Julio M. Pow-Sang, M.D., chair of Moffitt Cancer Center's Department of Genitourinary Oncology, and colleagues have published two prostate cancer articles in the September issue of JNCCN - The Journal of the National Comprehensive Cancer Network. The articles review and clarify recent updates made to the National Comprehensive Cancer Network's (NCCN) guidelines for the screening and treatment of prostate cancer.

29 Sep 2012

Exposure to phthalates increases risk of asthma-related airway inflammation in children

Children exposed to diethyl phthalate (DEP) and butylbenzyl phthalate (BBzP)-phthalate chemicals commonly found in personal care and plastic products-have elevated risk of asthma-related airway inflammation, according to researchers at Columbia Center for Children's Environmental Health (CCCEH) at the Mailman School of Public Health.

6 Sep 2012

Incentives can help promote drug abstinence among pregnant women with heroin or cocaine addiction

A "contingency management" approach—offering incentives for negative drug tests—can help promote drug abstinence among pregnant women with heroin or cocaine addiction, reports a study in the September Addictive Disorders & Their Treatment. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

1 Sep 2012

Exposure to BBzP during pregnancy can increase risk of eczema in children

Prenatal exposure to a ubiquitous household chemical called butylbenzyl phthalate (BBzP) can increase a child's risk for developing eczema, according to research conducted at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health.

26 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

DiagnoCure’s PCA3 prostate cancer diagnostic test showcased at AUA meeting

DiagnoCure Inc., a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the American Urological Association (AUA) meeting in Atlanta, GA.

25 May 2012